HOW DO FEMALE HORMONE LEVELS AFFECT THE HAEMOSTASIS DURING THE COURSE OF THE MENSTRUAL CYCLE?
Dr. Roza Chaireti
Sweden 
You need to have a Flash player to see the MULTIWEBCAST Viewer. Please click on the link below to download Flash Player.
Get Flash Player
8 slide(s) – English – 2012-06-29
HOW DO FEMALE HORMONE LEVELS AFFECT THE HAEMOSTASIS DURING THE MENSTRUAL CYCLE?
R. Chaireti 1,3, K. Bremme 2, B.Byström 2, K. M. Gustafsson 3, T. L. Lindahl 3
1 Department of Acute Internal Medicine, Acute Medicine and Coagulation Unit, Linköping University Hospital, Linköping, Sweden
2 Department of Women`s and Children´s Health, Division of Obstetrics and Gynecology , Karolinska Institutet, Stockholm, Sweden
3 Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
Background and Objectives: Although it is known that estrogens in oral contraceptives increase the levels of procoagulant variables and decrease the levels of coagulation inhibitors, the effect of the physiological concentrations of female hormones on coagulation is not as well studied. This report provides a structured analysis of the effects of progesterone (PGN), oestradiol (E2) and sex hormone-binding globulin (SHBG) on selected haemostatic variables during the follicular and the luteal phase of a normal menstrual cycle.
Subjects and Methods: The study cohort consisted of 102 healthy women who were not taking any form of hormone medication. The haemostatic variables analyzed were fibrinogen, factor II (FII), factor VII (FVII), factor VIII (FVIII), factor X (FX), D-dimer, von Willebrand factor (VWF) and antithrombin (AT). We used correlation analysis and simple regression analysis (as measurement for the effect) in order to evaluate our data.
Results: The correlations during the follicular phase were weak. PGN exhibited its strongest effect on fibrinogen (p=0,064). During the luteal phase, it was shown that PGN correlated positively with FII (0,225) and negatively with FVII (- 0,308). During this phase, PGN had a considerably stronger effect than oestradiol, especially on FII (p=0,04) and FVII (0,015). SHBG did not have any significant effect during both phases.
Conclusions: Although most previous studies report that PGN does not affect haemostasis, we found that PGN played a greater role than oestradiol, mainly in the luteal phase. That is consistent with the increase in PGN levels late in the menstrual cycle. Our findings suggest that the effect of PGN may be more central than previously thought and underline the need to perform more studies that do not focus solely on estrogens in order to better define the physiological effects
of hormonal changes on haemostasis.
|
|
